Amgen Milestones

2004

FDA approves Sensipar (cinacalcet HCl) for the treatment of secondary hyper-parathyroidism in chronic kidney disease patients on dialysis and for the treatment of elevated calcium levels (hypercalcemia) in patients with parathyroid carcinoma
FDA approves Enbrel for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy

2003

FDA approves Enbrel for the treatment of ankylosing spondylitis and other expanded indications

2002

FDA approves Enbrel to treat the signs and symptoms of active arthritis in patients with psoriatic arthritis
FDA approves Neulasta to decrease the incidence of infection in patients with non-myeloid cancers receiving myelosuppressive chemotherapy
Amgen completes Immunex acquisition
FDA approves Aranesp for the treatment of chemotherapy-induced anemia in patients with nonmyeloid malignancies
FDA approves Amgen's Rhode Island manufacturing facility for Enbrel

2001

FDA approves Kineret to treat the signs and symptoms in patients with moderately to severely active rheumatoid arthritis whose disease has failed to respond to one or more disease-modifying medicines
Kevin W. Sharer named chairman
FDA approves Aranesp to treat anemia associated with chronic renal failure, including patients on dialysis and not on dialysis

2000

1999

Gordon M. Binder retires
Amgen reaches sales of more than $3 billion
FDA approves Enbrel to treat patients with moderately to severely active polyarticular-course juvenile rheumatoid arthritis whose disease has failed to respond to prior disease-modifying medicines

1998

FDA approves Neupogen for use in support of treatment of acute myeloid leukemia
FDA approves Enbrel to treat patients with rheumatoid arthritis whose disease has failed to respond to prior disease-modifying medicines

1997

1996

FDA approves Epogen for reduction of allogeneic blood transfusion in surgery patients
Amgen reaches sales of more than $2 billion

1995

1994

FDA approves Neupogen for patients undergoing bone marrow transplantation and for patients with severe chronic neutropenia
Amgen receives U.S. Dept. of Commerce National Medal of Technology
Amgen completes acquisition of Synergen

1993

1992

1991

FDA approves Neupogen to decrease the incidence of infection associated with chemotherapy-induced neutropenia in patients with non-myeloid cancers receiving myelosuppressive therapy
Amgen establishes the Amgen Foundation for charitable giving
Neupogen named "Product of the Year" by Fortune magazine

1990

1989

Immunex clones TNF receptor, later patented and named Enbrel
Amgen receives first U.S. patent for recombinant G-CSF Neupogen
FDA approves Epogen for the treatment of anemia in patients with end-stage renal disease
Epogen named "Product of the Year" by Fortune magazine
Amgen added to the NASDAQ 100 Index

1988

1987

1986

1985

Larry M. Souza's team clones granulocyte colony-stimulating factor (G-CSF), later patented and named Neupogen

1983

Company changes name to Amgen
A team led by Fu-Kuen Lin clones erythropoietin, later patented and named Epogen
IPO of 2,350,000 shares at $18 per share results in $40 million raised; ticker symbol: AMGN

1981

1980

Venture capitalists Bill Bowes, Franklin "Pitch" Johnson, Sam Wohlsteadter and Raymond Baddour establish AMGen (Applied Molecular Genetics Inc.) as a California corporation on April 8
George B. Rathmann elected president and CEO